Cell-Based Therapies Progress
AMD-dry (RPE) – Astellas Phase 1/2
AMD-dry (RPE) – Cell Cure Phase 1/2
AMD-dry (RPE on scaffold) – Regen Patch Phase 1/2
RP, Usher (retinal progenitors) – jCyte Phase 2b
RP, Usher (retinal progenitors) – ReNeuron Phase 2
Stargardt (RPE) – Astellas Phase 1/2
Molecules, Proteins, AONs Progress
AMD-dry (C3 inhibitor) – Apellis Phase 3
AMD-dry (C5 inhibitor) – Ophthotech Phase 2
Bardet-Biedl (metformin) – Tubingen Hosp Phase 2 Pen.
LCA (CEP290, AON) – ProQR Phase 1/2
Stargardt disease (emixustat) – Acucela Phase 2
Stargardt disease (deuterated vit A) – Alkeus Phase 2
Stargardt disease (C5 inhibitor) – Ophthotech Phase 2
py Clinical-Trial Pipeline
es and Dry AMD: 33 trials
Visit www.ClinicalTrials.gov for more details and trial contact information.
This document is for informational purposes only. Information is subject to change,
and its accuracy cannot be guaranteed. Created June 2018.